Mitochondria as a therapeutic target for common pathologies

Murphy, M. P. and Hartley, R. C. (2018) Mitochondria as a therapeutic target for common pathologies. Nature Reviews Drug Discovery, 17, pp. 865-886. (doi: 10.1038/nrd.2018.174) (PMID:30393373)

166107.pdf - Accepted Version



Although the development of mitochondrial therapies has largely focused on diseases caused by mutations in mitochondrial DNA or in nuclear genes encoding mitochondrial proteins, it has been found that mitochondrial dysfunction also contributes to the pathology of many common disorders, including neurodegeneration, metabolic disease, heart failure, ischaemia–reperfusion injury and protozoal infections. Mitochondria therefore represent an important drug target for these highly prevalent diseases. Several strategies aimed at therapeutically restoring mitochondrial function are emerging, and a small number of agents have entered clinical trials. This Review discusses the opportunities and challenges faced for the further development of mitochondrial pharmacology for common pathologies.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Hartley, Professor Richard
Authors: Murphy, M. P., and Hartley, R. C.
College/School:College of Science and Engineering > School of Chemistry
Journal Name:Nature Reviews Drug Discovery
Publisher:Nature Publishing Group
ISSN (Online):1474-1784
Published Online:05 November 2018
Copyright Holders:Copyright © 2018 Springer Nature Limited
First Published:First published in Nature Reviews Drug Discovery 17:865-886
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
710821'Exploring mitochondrial metabolism in health and disease using targeted biological chemistryRichard HartleyWellcome Trust (WELLCOTR)110158/Z/15/ZCHEM - CHEMISTRY